Interní Med. 2009; 11(6): 263-266

New anticoagulants in the treatment of cardiovascular diseases

doc. MUDr. Debora Karetová CSc, prof. MUDr. Jan Bultas CSc
II. interní klinika kardiologie a angiologie 1. LF UK a VFN, Praha

Antithrombotics, i.e. antiplatelet drugs and anticoagulants are important pharmacologic groups, that are usefull for treatment of pandemy

of diseases on the base of atherothrombosis and thrombophilia. First part of this revue was dedicated to antiplatelet drugs in

previous issue (Interní Med 2009; 11(4): 174-177). The topics of this copy is inscribed to anticoagulants.

Keywords: anticoagulants, dabigatran, rivaroxaban, apixaban, idraparinux.

Published: July 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Karetová D, Bultas J. New anticoagulants in the treatment of cardiovascular diseases. Interní Med. 2009;11(6):263-266.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. DeCaterina R, et al. Anticoagulants in heart disease: current status and perspectives. Eur Heart J. 2007; 28 (7): 880-913. Go to original source... Go to PubMed...
    2. Mueck W, et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban-an oral, direct factor Xa inhibitor in patients undergoing major orthopaedic surgery. Clin Pharmacokinet. 2008; 47 (3): 203-216. Go to original source... Go to PubMed...
    3. Angiolillo DJ, et al. Clinical overview of promising nonthienopyridine antiplatelet agents. Am Heart J. 2008; 156 (2 Suppl): S23-28. Go to original source... Go to PubMed...
    4. Chintala M, et al. Basic and translational research on proteinase-activated receptors: antagonism of the proteinaseactivated receptor 1 for thrombin, a novel approach to antiplatelet therapy for atherothrombotic disease. J Pharmacol Sci. 2008; 108 (4): 433-438. Go to original source... Go to PubMed...
    5. Ezekowitz MD, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol. 2007; 100 (9): 1419-1426. Go to original source... Go to PubMed...
    6. Wolowacz SE, et al. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb Haemost. 2009; 101 (1): 77-85. Go to original source... Go to PubMed...
    7. Eikelbbom JE, Weitz JI. Dabigatran etexilate for prevention of venous thromboembolism. Tromb Haemost 2009; 101 (1): 2-4. Go to original source... Go to PubMed...
    8. Francis CW. New issues in oral anticoagulants. Hematology Am Soc Hematol Educ Program. 2008; 2008: 259-265. Go to original source... Go to PubMed...
    9. Baetz BE, Spinler SA. Dabigatran etexilate: an oral direct trombin inhibitor for prophylaxis and treatment of thromboembolic diseases. Pharmacotherapy 2008; 28 (11): 1354-1373. Go to original source... Go to PubMed...
    10. Usman MH, Notato LA, Patel H, et al. New developments in anticoagulation for atrial fibrillation. Curr Treat Options Cardiovasc Med 2008; 10 (5): 388-397. Go to original source... Go to PubMed...
    11. Sanford M, Ploskem GL. Dabigatran etexilate. Drugs 2008; 68 (12): 1699-1709. Go to original source... Go to PubMed...
    12. The RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 2765-2774. Go to original source... Go to PubMed...
    13. RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008; 358: 2776-2786.
    14. Larsen MR, Davidsen BL, Gallus A, et al. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Tromb Haemost. 2007; 5: 2368-2375. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.